<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9640729</article-id>
    <article-id pub-id-type="publisher-id">23649</article-id>
    <article-id pub-id-type="doi">10.1038/s41598-022-23649-0</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Machine learning based personalized drug response prediction for lung cancer patients</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Qureshi</surname>
          <given-names>Rizwan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Basit</surname>
          <given-names>Syed Abdullah</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shamsi</surname>
          <given-names>Jawwad A.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fan</surname>
          <given-names>Xinqi</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nawaz</surname>
          <given-names>Mehmood</given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yan</surname>
          <given-names>Hong</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Alam</surname>
          <given-names>Tanvir</given-names>
        </name>
        <address>
          <email>talam@hbku.edu.qa</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.452146.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1789 3191</institution-id><institution>College of Science and Engineering, </institution><institution>Hamad Bin Khalifa University, </institution></institution-wrap>Doha, Qatar </aff>
      <aff id="Aff2"><label>2</label>FAST National University of Computer and Emerging Sciences, Karachi, Pakistan </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.35030.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 1792 6846</institution-id><institution>Department of Electrical Engineering, </institution><institution>City University of Hong Kong, </institution></institution-wrap>Kowloon, Hong Kong </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.35030.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 1792 6846</institution-id><institution>Center for Intelligent Multidimensional Data Analysis (CIMDA), </institution><institution>City University of Hong Kong, </institution></institution-wrap>Kowloon, Hong Kong </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Department of Biomedical Engineering, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Shatin, Hong Kong, SAR China </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>7</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>7</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>18935</elocation-id>
    <history>
      <date date-type="received">
        <day>30</day>
        <month>4</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>3</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affect treatment plans and treatment efficacy may be lost after about a year. Predicting the response to EGFR-TKIs for EGFR-mutated lung cancer patients is a key research area. In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, in lung cancer patients. The patient’s mutation status is taken into consideration in molecular dynamics (MD) simulation. Each patient’s unique mutation status was modeled considering MD simulation to extract molecular-level geometric features. Moreover, additional clinical features were incorporated into machine learning model for drug response prediction. The complete feature set includes demographic and clinical information (DCI), geometrical properties of the drug-target binding site, and the binding free energy of the drug-target complex from the MD simulation. PDRP incorporates an XGBoost classifier, which achieves state-of-the-art performance with 97.5% accuracy, 93% recall, 96.5% precision, and 94% F1-score, for a 4-class drug response prediction task. We found that modeling the geometry of the binding pocket combined with binding free energy is a good predictor for drug response. However, we observed that clinical information had a little impact on the performance of the model. The proposed model could be tested on other types of cancers. We believe PDRP will support the planning of effective treatment regimes based on clinical-genomic information. The source code and related files are available on GitHub at:  <ext-link ext-link-type="uri" xlink:href="https://github.com/rizwanqureshi123/PDRP/">https://github.com/rizwanqureshi123/PDRP/</ext-link>.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Computer science</kwd>
      <kwd>Lung cancer</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">Lung cancer is a leading cause of deaths worldwide<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, and has the lowest survival rate among all cancer types. It is the second most common type of cancer, and often diagnosed at later stages when metastatic spread to other parts of the body may have occurred<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. In the last decade, rapid progress has been made in the management of non-small cell lung cancer (NSCLC) patients. Molecular targeting has made great advances, and epidermal growth factor receptor (EGFR) and ErbB family members have been identified as useful therapeutic targets<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Over-expression of EGFR is found in about 60% of advanced NSCLC patients<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. The US Food and Drug Administration (FDA) has approved three generations of small molecule tyrosine kinase inhibitors (TKIs) Gefitinib/Erlotinib/Afatinib/Osimertinib as a first line treatment for lung cancer patients harboring EGFR mutations<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. These TKIs produced encouraging results at the initial stage of therapy and increased the survival rate and quality of life of patients<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. However, resistance to these drugs has appeared in many cases<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. A major cause of this resistance is a secondary point mutation in the kinase domain of EGFR<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p>
    <p id="Par3">Several studies have attempted to decode the mechanism of drug resistance in EGFR-mutated lung cancer<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. These studies found many reasons, such as the secondary point mutation T790M<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, breaking of the hydrogen bond at site 790, and reactivation of AKT<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. <italic>In silico</italic> methods have been extensively applied to study these drug resistance mechanisms<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Molecular dynamics (MD) simulation<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> is a computational tool, which has been used to understand dynamics<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, stability<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, and structural variations<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Recently, a framework has been developed for the visualization of protein-drug interactions in the analysis of drug resistance in lung cancer<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. There is still much unexplained variation in patients’ responses to these drugs and clinical-genomic features of patients may play a significant role underlying the mechanism of drug resistance<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and patient stratification<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p>
    <p id="Par4">The completion of the human genome project<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> allowed a shift of paradigm from the traditional medical model of targeting large populations to precision therapies<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Information from genomics and electronic health records provides novel opportunities for patient care, prevention, and devising optimal treatment strategies<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Predicting a patient’s response to a drug treatment, or identifying their optimal treatment strategy, such as the combinations and doses of drugs, is challenging for computational methods due to limited data sources, disparity among labels and unknown biological evidence<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. The position of the drug-binding site, binding free energy, geometrical features, and clinical information may be used to model multi-class drug responses<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. The protein data bank (PDB)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> contains several high-resolution structures of EGFR bound to different generations of approved drugs, providing opportunities to build structure-based data-driven models. An EGFR-L858R dimer with Gefitinib is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>An EGFR-Gefitinib complex modeled with the L858R mutation. The drug molecule is indicated by the black square and the mutation by the red circle. The image was generated using PyMol.</p></caption><graphic xlink:href="41598_2022_23649_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par5">As drug responses are often mediated by protein-drug interactions, the geometry of the drug-target binding site or pocket can be a useful predictor of drug response. MD simulation of the binding energy of drug-mutant complexes and related personal characteristics of patients, when used as input to an extreme learning machine (ELM)<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, classified drug response levels into two classes<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, with an accuracy of 95.3%. Combining local geometrical properties with energy related features in an Eigen binding site method achieved an average accuracy of 69.35% in predicting four classes of drug responses<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Patients’ demographic and lifestyle patterns and geometric features of drugs were used for a similar predictive model<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, and protein-drug interaction footprint tensors were used in a three-level drug response predictive model<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
    <p id="Par6">While these studies demonstrate the potential of combining dynamic molecular features with patient data to predict responses to a drug, the quality of the predictions needs to be improved if they are to be of clinical use. In this work, we combined the geometric information of the drug-target binding site, the binding energy, and patient’s clinical information to predict four classes of drug response with an imbalanced dataset. The proposed personalized drug response prediction (PDRP) model achieves state of the art performance in predicting drug responses. The main contributions of this work are:<list list-type="bullet"><list-item><p id="Par7">We have developed a drug response prediction model using molecular dynamics (MD) simulation and machine learning (ML), which achieves state of the art performance.</p></list-item><list-item><p id="Par8">We have proposed a set of novel geometric features by modelling the binding site of drug-target complex. Our work demonstrates the contribution of the geometrical features of binding sites in improving the predictive accuracy of our ML model.</p></list-item><list-item><p id="Par9">The proposed model, PDRP, is a generic concept, which can be used for other cancers or diseases with minor modifications, with potential applications in clinical decision support systems and patient stratification.</p></list-item></list></p>
  </sec>
  <sec id="Sec2">
    <title>Results</title>
    <p id="Par10">In this work, we have developed a drug-response predictive model for lung cancer patients. Demographic and clinical information, such as age, gender, survival time, smoking history, tumor progression level and type of mutation, were collated from previous studies<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref></sup>. We simulated EGFR-Gefitinib complexes in the AMBER software suite<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> for 2 ns and extracted the trajectories. Based on the simulated trajectories, we proposed novel geometrical features <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g1}$$\end{document}</tex-math><mml:math id="M2"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq1.gif"/></alternatives></inline-formula> (the matching rate, number of connected atoms, and number of hydrogen bonds) and <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g2}$$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq2.gif"/></alternatives></inline-formula> (the number of convex atoms and Euclidean distance) from the EGFR mutant-drug complexes to predict the drug-response level as one of complete response, partial response, stable disease or progressive disease. We also used binding free energy as a feature in the machine learning model. The combination of clinical, geometric and energy related features boosted the performance of the machine learning model.</p>
    <sec id="Sec3">
      <title>Baseline statistics</title>
      <p id="Par11">201 NSCLC patients form the cohort of this study. The patients had a median age of 63 years, 35% (71) were female and 65% (130) male, and about 75% were non-smokers. All patients received EGFR-TKIs as their first line of treatment. Response levels 0 and 1 indicate complete and partial responses to the drug. Response levels 2 and 3 correspond to stable and progressive disease (No response). The dataset used here consisted of 19, 118, 30, 34 patients at response levels 0, 1, 2 and 3, corresponding to complete, partial, stable, and progressive disease (No response), respectively.</p>
    </sec>
    <sec id="Sec4">
      <title>Proposed feature set summary</title>
      <p id="Par12">For a patient, his/her demographic and clinical information (DCI), the energy and geometric features of their mutant EGFR-Gefitinib complex were obtained and used to predict their drug response level through machine learning classifiers. A detailed description of the features and their value ranges are presented in Table <xref rid="Tab1" ref-type="table">1</xref>. In total we extracted 4, 4, and 5 features from DCI, energy and geometric types, respectively. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows the box plot for different features and the correlations among them.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical information, energy and geometrical features: description and values.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Feature type</th><th align="left">Attributes</th><th align="left">Description</th><th align="left">Discrete/Continuous</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left" rowspan="4">DCI</td><td align="left">Age</td><td align="left" rowspan="4">Patient’s personal information</td><td align="left">Discrete</td><td align="left">[0–4]</td></tr><tr><td align="left">Sex</td><td align="left">Discrete</td><td align="left">[0–2]</td></tr><tr><td align="left">Smoking history</td><td align="left">Discrete</td><td align="left">[0–2]</td></tr><tr><td align="left">Response status</td><td align="left">Discrete</td><td align="left">[0–3]</td></tr><tr><td align="left" rowspan="4">Energy</td><td align="left">VDW</td><td align="left">Van der Walls energy</td><td align="left">Continuous</td><td align="left">[− 60 to − 45]</td></tr><tr><td align="left">EEL</td><td align="left">Electrostatic interactions</td><td align="left">Continuous</td><td align="left">[− 23–11]</td></tr><tr><td align="left">ESURF</td><td align="left">No polar component of the solvation energy</td><td align="left">Continuous</td><td align="left">[− 45 to − 1]</td></tr><tr><td align="left">EPB</td><td align="left">Polar component of solvation free energy</td><td align="left">Continuous</td><td align="left">[27–40]</td></tr><tr><td align="left" rowspan="5">Geometric</td><td align="left">Matching rates</td><td align="left">Matched atoms</td><td align="left">Discrete</td><td align="left">[0, 17]</td></tr><tr><td align="left">Convex atoms</td><td align="left">Strength of interaction</td><td align="left">Discrete</td><td align="left">[0, 43]</td></tr><tr><td align="left">Connectivity</td><td align="left">Connected atoms</td><td align="left">Discrete</td><td align="left">[0, 23]</td></tr><tr><td align="left">Euclidean distance</td><td align="left">Distance between drug and target</td><td align="left">Continuous</td><td align="left">[30–39]</td></tr><tr><td align="left">Hydrogen bonds</td><td align="left">Number of hydrogen bonds</td><td align="left">Discrete</td><td align="left">[775–1650]</td></tr></tbody></table></table-wrap></p>
      <p id="Par13">
        <fig id="Fig2">
          <label>Figure 2</label>
          <caption>
            <p>Box plot of normalized values for energy, and geometrical features (left panel), and correlation among features (right panel).</p>
          </caption>
          <graphic xlink:href="41598_2022_23649_Fig2_HTML" id="MO2"/>
        </fig>
      </p>
      <p id="Par14">A total of 33 different EGFR mutations occurred in these patients. The root mean square deviations (RMSD) of the trajectories from MD simulations of WT and four mutants and the patient disease response classification by mutation type are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The most common mutations were L858R, delE746−750 and L858R−T790M. All mutations were modelled based on the EGFR 3D structure using Rosetta<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. The potency of an inhibitor can be measured by the time a patient survives and their drug response level. The relationship between the drug response and the personal and energy features were not linearly, or one-to-one, related to drug response or survival time (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Drug response was classified into four levels, based on the response evaluation criteria in solid tumors (RECIST)<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. A list of mutations types is provided in the Supplementary File <xref rid="MOESM1" ref-type="media">S1</xref>.<fig id="Fig3"><label>Figure 3</label><caption><p>(<bold>a</bold>) MD trajectories of EGFR and some mutants showing RMSD from the reference structure. As the values are below 5, the structures are reliable for further analysis. (<bold>b</bold>) Distribution of disease response classifications for 201 patients by the three most common mutations (L858R, L858R-T790M, del E746-750), and the others.</p></caption><graphic xlink:href="41598_2022_23649_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>Disease response classification and survival time (months) by binding free energy (left panel) and disease response classification and survival time (years) by age of patient (right panel).</p></caption><graphic xlink:href="41598_2022_23649_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec5">
      <title>Performance of the proposed PDRP model</title>
      <p id="Par15">To build the PDRP model, we incorporated clinical information, MD simulation results and novel geometric features from the protein–drug interactions. An ablation study, based on each type of feature and the corresponding model’s performance, showed that the geometrical features were the most powerful predictors, followed by DCI and energy-related features (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Of the models tested, XGboost had the best performance. Demographic and clinical features brought a little improvement to the performance, and the combination of all three types of features boosted the performance in XGboost, Random Forest and the Neural Network.<fig id="Fig5"><label>Figure 5</label><caption><p>Contribution of geometrical, DCI, and energy-related features to the accuracy of the model.</p></caption><graphic xlink:href="41598_2022_23649_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>Ablation study on geometric features.</p></caption><graphic xlink:href="41598_2022_23649_Fig6_HTML" id="MO6"/></fig></p>
      <p id="Par16">The confusion matrices for the training and classification reports are shown in Figs. <xref rid="Fig7" ref-type="fig">7</xref> and <xref rid="Fig8" ref-type="fig">8</xref> , respectively. The XGboost classifier achieved 97.5% accuracy, 97% recall, 93% precision, and 97% F1-score with only two mis-classifications for an independent testing set of 61 samples. The performance of the random forest and neural network and were close to, but not better than, XGboost. The classifiers were trained using a nested-cross validation approach, and the parameters of classifiers were optimized using a grid search approach.<fig id="Fig7"><label>Figure 7</label><caption><p>Confusion matrix for testing dataset.</p></caption><graphic xlink:href="41598_2022_23649_Fig7_HTML" id="MO7"/></fig><fig id="Fig8"><label>Figure 8</label><caption><p>Classification performance on testing dataset.</p></caption><graphic xlink:href="41598_2022_23649_Fig8_HTML" id="MO8"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec6">
    <title>Discussion</title>
    <p id="Par17">Our main focus in this work was on modeling the geometry of the drug-binding pocket and combining this with the demographic and clinical information (DCI) of the patients. The geometrical features (the number of convex atoms at the interaction surface of the complex, the matching rates of surface atoms, the dynamic distances between the center of the drug molecule and binding-site residues throughout the trajectory, and the number of hydrogen bonds) were the most discriminative features. Combining clinical and molecular predictors to identify drug-sensitive patients was most effective. The mutation changes the shape and structure of the drug binding complex, which leads to changes in the values of the geometrical features and thus the drug response. Further investigation of this model may result in geometrical features that better stratify patients based on mutation, age or gender specific therapies and the model might also help in selecting the optimal drug for specific patients. In addition, we perform another ablation study only on geometric features. We found that geometric feature 2 has more predictive capability than geometric feature 1. However combining the feature further boosts the performance, as shown in Fig. <xref rid="Fig6" ref-type="fig">6</xref>. Moreover, It will be interesting to see the performance of modern geometrical based deep learning algorithms<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, if a large number of samples are available.</p>
    <sec id="Sec7">
      <title>Comparison against other methods</title>
      <p id="Par18">Table <xref rid="Tab3" ref-type="table">3</xref> shows that the classification accuracy of the proposed method achieved state of the art performance relative to related works and achieved this while predicting the highest number of classes (four) of drug responses. Methods predicting fewer response levels performed better than earlier four-level predictors, however, our method outperformed all previous work. The combination of geometrical, energy, and personal features seems to be a more optimal strategy for predicting the drug response. The highly accurate pioneering work<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> used binding free energy, and personal features of 168 patients but only predicted a two-class drug response. Figure <xref rid="Fig5" ref-type="fig">5</xref> shows the contribution of each feature. The demographic and clinical (DCI) feature slightly improved the drug response prediction as shown in Table <xref rid="Tab2" ref-type="table">2</xref>. To further test the performance of the proposed model, we convert our problem into 2 class binary classification. We combined partial response and full response to one class, and stable disease and no response to another class. After that, we re-run the method proposed by<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> and<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> on our task. The results are shown in Table  <xref rid="Tab3" ref-type="table">3</xref>. Our method also performs well on binary classification problem.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of PDRP with other methods.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Reference</th><th align="left">Patients</th><th align="left">Features</th><th align="left">Method</th><th align="left">Response level</th><th align="left">Accuracy</th></tr></thead><tbody><tr><td align="left"><sup><xref ref-type="bibr" rid="CR13">13</xref></sup></td><td align="left">167</td><td align="left">Personal and energy</td><td align="left">Extreme learning machines</td><td align="left">2</td><td align="left">95.13</td></tr><tr><td align="left"><sup><xref ref-type="bibr" rid="CR39">39</xref></sup></td><td align="left">355</td><td align="left">Personal and genetic</td><td align="left">Sequential minimization optimization</td><td align="left">2</td><td align="left">76.56</td></tr><tr><td align="left"><sup><xref ref-type="bibr" rid="CR30">30</xref></sup></td><td align="left">137</td><td align="left">Geometrical and personal</td><td align="left">Softmax regression</td><td align="left">4</td><td align="left">70.78</td></tr><tr><td align="left"><sup><xref ref-type="bibr" rid="CR26">26</xref></sup></td><td align="left">311</td><td align="left">Energy and geometrical</td><td align="left">Support vector machine</td><td align="left">4</td><td align="left">69.35</td></tr><tr><td align="left"><sup><xref ref-type="bibr" rid="CR31">31</xref></sup></td><td align="left">NA</td><td align="left">Protein-drug interactions</td><td align="left">Naive Bayes</td><td align="left">3</td><td align="left">95.50</td></tr><tr><td align="left">PDRP</td><td align="left">201</td><td align="left">DCI, Energy, Geometric</td><td align="left">XGboost</td><td align="left">4</td><td align="left"><bold>97.50</bold></td></tr></tbody></table><table-wrap-foot><p>The best accuracy is in bold.</p><p>The 2-class response includes complete response and no-response, while 3-class response includes low, moderate, and full response. The 4-class response includes complete-response, partial-response, no-response, and progresive disease.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparative results on binary class problem.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Reference</th><th align="left">Method</th><th align="left">Accuracy</th></tr></thead><tbody><tr><td align="left"><sup><xref ref-type="bibr" rid="CR13">13</xref></sup></td><td align="left">Extreme learning machines</td><td align="left">89.13</td></tr><tr><td align="left"><sup><xref ref-type="bibr" rid="CR39">39</xref></sup></td><td align="left">Sequential minimization optimization</td><td align="left">79.58</td></tr><tr><td align="left">PDRP</td><td align="left">XGboost</td><td align="left"><bold>98.50</bold></td></tr></tbody></table><table-wrap-foot><p>The best accuracy is in bold.</p><p>We converted partial response and full response to a single class “response”; and no response and stable disease to a single class “no response”.</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec8">
      <title>Performance of PDRP on gender stratified samples</title>
      <p id="Par19">Experiments using PDRP on gender stratified samples showed that the model performed well on both male and female patients (Fig. <xref rid="Fig9" ref-type="fig">9</xref>). Drug responses were correctly identified in 21 females patients with no mis-classification. However, there were two mis-classifications, between partial and complete responses, in the male dataset of 39 patients.<fig id="Fig9"><label>Figure 9</label><caption><p>Confusion matrices for the XGBoost model on gender-stratified patients.</p></caption><graphic xlink:href="41598_2022_23649_Fig9_HTML" id="MO9"/></fig></p>
    </sec>
    <sec id="Sec9">
      <title>Translation research</title>
      <p id="Par20">In this paper, we proposed two novel composite features. Composite feature <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g1}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq3.gif"/></alternatives></inline-formula> captures the interaction strength of the protein-drug complex, and composite feature <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g2}$$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq4.gif"/></alternatives></inline-formula> captures the shape and local surface information of the protein-drug complex. The morphological properties of the binding site, the number of convex atoms and the dynamic distance help us to model the geometrical properties. Length and strength of protein-drug interactions are represented by these features, which helps in predicting the drug-response. The features that play a prominent role in the drug response could be further studied to screen inhibitors for personalized therapy and may become useful biomarkers for drug screening. We also showed that combining DCI, geometrical and energy related features helps to boost the performance of the drug response prediction model.</p>
    </sec>
    <sec id="Sec10">
      <title>Limitations</title>
      <p id="Par21">A limitation of this study is that it contained only the 33 most common EGFR mutations from the 594 EGFR mutations available in COSMIC database<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. However, the mutations studied account for about 90% of all mutations. It is difficult to determine drug sensitivity to rare mutations due to limited patient data. Another limitation is the small dataset of 201 patients. Obtaining clinical data is difficult due to privacy and ethical considerations. Most clinical studies consist of fewer than 400 patients (Table <xref rid="Tab3" ref-type="table">3</xref>) and may have imbalanced numbers of patients at each response level. Despite this, our model achieved a highly accurate prediction rate.</p>
      <p id="Par22">Protein-ligand interactions usually take place in nanoseconds, so our simulation is adequate. Many of the previous studies on EGFR drug response prediction also used 2-ns MD simulation<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. However, the time scale is highly case-specific and may cause computing costs to explode. Of course, it would be useful to study the interactions for longer time, but MD simulations only provide an approximate solution, and the later part of the simulations can be less accurate. Quantum mechanics (QM)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> based analysis would be more accurate, but the computational cost is currently beyond the reach of most computers unless we only deal with very small molecules.</p>
    </sec>
  </sec>
  <sec id="Sec11">
    <title>Methods</title>
    <p id="Par23">The framework to classify individual patient outcomes is divided into three modules: computational modeling of mutant/drug structures, MD simulations, and classification. Figure <xref rid="Fig10" ref-type="fig">10</xref>a shows a method for computationally modeling the structure of the EGFR-Gefitinib drug complex; PDB 2ITY was used as the template structure. Figure <xref rid="Fig10" ref-type="fig">10</xref>b and c show the steps of the MD simulation and the formulation of the classification models. Each mutation was modeled in the 3D structure of the protein-drug complex. Our dataset consisted of 33 different EGFR point mutations. For each mutant, MD simulations were performed and the binding free energy was calculated. Multiple machine learning models were used to predict the response level.<fig id="Fig10"><label>Figure 10</label><caption><p>The framework for predicting the drug response in lung cancer patients based on personal data, binding energy, and geometric features. Mutant structures are predicted by computational methods then molecular dynamics simulations extract energy and geometrical features. Machine learning classifiers then predict four classes of drug response from these features.</p></caption><graphic xlink:href="41598_2022_23649_Fig10_HTML" id="MO10"/></fig></p>
    <sec id="Sec12">
      <title>Dataset collection</title>
      <p id="Par24">All the methods under this study were performed in accordance with the relevant guidelines and regulations of City University of Hong Kong (CityU). Informed consent was taken from all participants.The experimental protocols were approved by the Institutional Review Board (IRB) of City University of Hong Kong. The clinical information used in this study was collected from several published sources<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref></sup>. A dataset of 201 NSCLC patients was obtained and 140 samples were used to train the model. 61 independent samples were used to test the model, with 3, 5, 36, and 17 samples for stable disease, no response, partial response and complete response respectively. The L858R mutation was the most frequent mutation, followed by secondary point mutation L858R-T790M and delE746-750, as shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>b. The EGFR mutations were selected based on a survey in<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
    </sec>
    <sec id="Sec13">
      <title>Demographic and clinical information (DCI)</title>
      <p id="Par25">Demographic information such as age, sex, smoking history as well as clinical information such as survival [0,1], drug response level and performance status were extracted from the clinical dataset. Age was encoded between 0 to 4 based on the age brackets (0,40), (41, 50), (51, 60), (61, 70), and (71 and above), due to inherent modes.</p>
    </sec>
    <sec id="Sec14">
      <title>Modeling of 3D structures</title>
      <p id="Par26">The 3D mutant structures were predicted based on the crystal structure of wildtype EGFR taken from Protein Data Bank (PDB)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> with PDB ID 2ITY. The high resolution ddgmonomer (HRDM)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> protocol in Rosetta was used to predict point mutations, and the comparative modeling protocol was used to predict multi-point mutations<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Quality assessment of predicted structures was performed by Verify3D<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, and Q-mean<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
    </sec>
    <sec id="Sec15">
      <title>Molecular dynamics simulation</title>
      <p id="Par27">MD simulations of the protein-drug complex were performed using the QM/MM method in Amber<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> with a surrounding waterbox neutralized using Na+ and Cl- atoms and the ff9SB<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> and GAFF force fields. The total energy of the system was the summation of bonded (stretch, bend, torsion) and non-bonded (electrostatic, van der Waals) terms.<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} E_{total} = E_{stretch} + E_{bend} + E_{torsion} + E_{electrostatic} + E_{vdw} \end{aligned}$$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">stretch</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">bend</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">torsion</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">electrostatic</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi mathvariant="italic">vdw</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par28">Energy minimization was used to refine the modeled structure before the MD run, which begins with the system being heated from 0K to 300K, followed by equilibration at constant pressure and density for 500-ps and 50-ps respectively. The SHAKE algorithm<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> was utilized to control temperature and constrain bond stretching. After reaching a stable state, MD simulation runs were carried out for 2-ns at a steady temperature (300K) and pressure (1 Atm). A twelve core 3.47 GHz CPU with eight GB RAM was used to run MD simulations.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, with a Tesla C2075 GPU<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> used in production runs. Each simulation took roughly 12 h to complete. The trajectory was extracted using the CPPTRAJ<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> package in Amber, with frames gathered every 10-ps, producing 200 frames per run.</p>
      <sec id="Sec16">
        <title>Binding free energy</title>
        <p id="Par29">The free energy of binding<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> of a drug to a protein in a solvated environment estimates the binding affinity<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. The parallel version of MM-GBSA<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> on a twelve core, 3.47 GHz CPU was used for the simulation. The MD trajectory was considered as input to MM-GBSA. Each round of simulation took on average twelve hours for computation. The binding free energy is calculated based on the theory of the thermodynamic cycle in vacuum and solvated environments<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> as:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \begin{aligned} \Delta {G} = \Delta {G}_{Bind, Vacuum} + \Delta {G}_{Solv, Complex} \\ - (\Delta {G}_{Solv, ligand} + \Delta {G}_{Solv, Receptor}) \end{aligned} \end{aligned}$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>V</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>u</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow/><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq5"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta {G}$$\end{document}</tex-math><mml:math id="M14"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq5.gif"/></alternatives></inline-formula> is the binding free energy difference of the receptor-ligand system in a vacuum. <inline-formula id="IEq6"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta {G}_{Solv, Complex}$$\end{document}</tex-math><mml:math id="M16"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq6.gif"/></alternatives></inline-formula>, <inline-formula id="IEq7"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta {G}_{Solv, ligand}$$\end{document}</tex-math><mml:math id="M18"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq7.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq8"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta {G}_{Solv, Receptor}$$\end{document}</tex-math><mml:math id="M20"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq8.gif"/></alternatives></inline-formula> represent their energy differences between vacuum and solvent states. The energy component is composed of Van der Waals forces (VDW), electrostatic energy (EEL), the electrostatic contribution to solvation, and non-polar contributions to the solvation free energy (ESURF).</p>
      </sec>
    </sec>
    <sec id="Sec17">
      <title>Geometric features</title>
      <p id="Par30">Interactions between the binding site residues of a protein and small molecule inhibitors are commonly used in prediction methods<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. Local geometric surface properties were determined based on the alpha shape<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> using the computational geometry algorithm library (CGAL)<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p>
      <sec id="Sec18">
        <title>Convex atoms</title>
        <p id="Par31">Each atom in a drug-mutant system has a position and mass, represented as a = (<italic>p, w</italic>), where <italic>p</italic> is the position and <italic>w</italic> is the mass of the atom. Two atoms <inline-formula id="IEq9"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {a}_1$$\end{document}</tex-math><mml:math id="M22"><mml:msub><mml:mtext>a</mml:mtext><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq9.gif"/></alternatives></inline-formula> = (<inline-formula id="IEq10"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${p}_1$$\end{document}</tex-math><mml:math id="M24"><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq10.gif"/></alternatives></inline-formula>, <inline-formula id="IEq11"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${w}_1$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mi>w</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq11.gif"/></alternatives></inline-formula>) and <inline-formula id="IEq12"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {a}_2$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mtext>a</mml:mtext><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq12.gif"/></alternatives></inline-formula> = (<inline-formula id="IEq13"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${p}_2$$\end{document}</tex-math><mml:math id="M30"><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq13.gif"/></alternatives></inline-formula>, <inline-formula id="IEq14"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${w}_2$$\end{document}</tex-math><mml:math id="M32"><mml:msub><mml:mi>w</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq14.gif"/></alternatives></inline-formula>) are defined as orthogonal or sub-orthogonal using the following equation.<disp-formula id="Equ18"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} {\left\{ \begin{array}{ll} |p_{1}p_{2}| = w_{1} + w_{2}, &amp;{} a_{1} \perp a_{2} \\ |p_{1}p_{2}| = w_{1} &gt; w_{2}, &amp;{} a_{1} \perp _{s} a_{2} \\ \end{array}\right. } \end{aligned}$$\end{document}</tex-math><mml:math id="M34" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mo>=</mml:mo></mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⊥</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mrow/><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mo>=</mml:mo></mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mo>⊥</mml:mo><mml:mi>s</mml:mi></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ18.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par32">From the alpha shape, the solid angle<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> of atoms was determined to characterize the geometric properties of the local surface. If A, B, C, and D are the vertices of a tetrahedron, the solid angle, <inline-formula id="IEq15"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\Omega }_i$$\end{document}</tex-math><mml:math id="M36"><mml:msub><mml:mi mathvariant="normal">Ω</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq15.gif"/></alternatives></inline-formula>, is:<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \Omega _i = \sum _i (\phi _i^{AB} + \phi _i^{BC} + \phi _i^{AC} - \pi ), \end{aligned}$$\end{document}</tex-math><mml:math id="M38" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Ω</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">AB</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">BC</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">AC</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mi>π</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq16"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\phi _i^{AB}$$\end{document}</tex-math><mml:math id="M40"><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">AB</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq16.gif"/></alternatives></inline-formula>, <inline-formula id="IEq17"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\phi _i^{BC}$$\end{document}</tex-math><mml:math id="M42"><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">BC</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq17.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq18"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\phi _i^{BC}$$\end{document}</tex-math><mml:math id="M44"><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">BC</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq18.gif"/></alternatives></inline-formula> represent the dihedral angles of tetrahedron <italic>i</italic>.<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \Omega ' = \frac{cos(\Omega _i)}{4}, \end{aligned}$$\end{document}</tex-math><mml:math id="M46" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msup><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ω</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>4</mml:mn></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par33"><inline-formula id="IEq19"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Omega '$$\end{document}</tex-math><mml:math id="M48"><mml:msup><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq19.gif"/></alternatives></inline-formula> results in a convex shape if positive and a concave shape if negative (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). The number of atoms in a convex shape at the local surface of the drug-dimer complex was used.<fig id="Fig11"><label>Figure 11</label><caption><p>Atoms in convex and concave shapes at the surface curvature. The figure at the top shows a matched concave-convex pair, thus a strong interaction, while the figure at the bottom shows an unmatched pair and a weak interaction.</p></caption><graphic xlink:href="41598_2022_23649_Fig11_HTML" id="MO16"/></fig></p>
      </sec>
      <sec id="Sec19">
        <title>Matching rates</title>
        <p id="Par34">The atoms at the interface of the structures create the interaction between the drug and the target. The surface atoms were collected using the alpha shape algorithm, and named as point set A. After that, point sets B and C were obtained, to represent the surface atoms of the target and the drug, respectively. The interacting atoms (<italic>I</italic>) were obtained using set operations and further classified as, interacting atoms in the drug, <inline-formula id="IEq20"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$I_d$$\end{document}</tex-math><mml:math id="M50"><mml:msub><mml:mi>I</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq20.gif"/></alternatives></inline-formula>, or target, <inline-formula id="IEq21"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$I_t$$\end{document}</tex-math><mml:math id="M52"><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq21.gif"/></alternatives></inline-formula>, according to the following equation:<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} {\left\{ \begin{array}{ll} I = (B~\cup ~C) - A \\ I_t = (I~\cap ~B) \\ I_d = (I~\cap ~C).\\ \end{array}\right. } \end{aligned}$$\end{document}</tex-math><mml:math id="M54" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>B</mml:mi><mml:mspace width="3.33333pt"/><mml:mo>∪</mml:mo><mml:mspace width="3.33333pt"/><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>-</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:mspace width="3.33333pt"/><mml:mo>∩</mml:mo><mml:mspace width="3.33333pt"/><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:msub><mml:mi>I</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:mspace width="3.33333pt"/><mml:mo>∩</mml:mo><mml:mspace width="3.33333pt"/><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par35">The matching rate was determined by selecting atoms at the drug and the target. If one of the atoms is convex and other is concave, the pair is recorded as matched and there is a strong interaction between them. If both atoms are convex or concave, the pair is unmatched, and the interaction is weak, as shown in Fig. <xref rid="Fig11" ref-type="fig">11</xref>. The matched and unmatched atoms are determined as:<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} f(B, C) = {\left\{ \begin{array}{ll} 1&amp;{}~\Omega _B~\times ~\Omega _C~&lt; 0 \\ 0&amp;{}otherwise \\ \end{array}\right. } \end{aligned}$$\end{document}</tex-math><mml:math id="M56" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mspace width="3.33333pt"/><mml:msub><mml:mi mathvariant="normal">Ω</mml:mi><mml:mi>B</mml:mi></mml:msub><mml:mspace width="3.33333pt"/><mml:mo>×</mml:mo><mml:mspace width="3.33333pt"/><mml:msub><mml:mi mathvariant="normal">Ω</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mspace width="3.33333pt"/><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mn>0</mml:mn></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula>Matching rates are calculated for each frame of the MD trajectory as:<disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} MR = \frac{\sum _{i, j}f(B_i, C_j)}{N} \end{aligned}$$\end{document}</tex-math><mml:math id="M58" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>M</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ7.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par36"><italic>MR</italic> represents the matching rate, <inline-formula id="IEq22"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f(B_i, C_j)$$\end{document}</tex-math><mml:math id="M60"><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq22.gif"/></alternatives></inline-formula> is a matched atom pair, and <italic>N</italic> is the total number of MD snapshots. The matching rate is used as a feature in this work, and low matching rates were linked to low drug responses.</p>
      </sec>
      <sec id="Sec20">
        <title>Connectivity measure</title>
        <p id="Par37">Connectivity changes between binding site residues and the drug molecule throughout the MD simulation. We define a local threshold value of 40 based on Euclidean distance and then record the number of atoms that remain within this threshold throughout the MD Simulation. The consistency of these connections may identify critical atoms and could be used as a predictor of the drug response level:<disp-formula id="Equ8"><label>8</label><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} C_{k, i} = \sum _j A_{k, i , j} \end{aligned}$$\end{document}</tex-math><mml:math id="M62" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ8.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq23"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {A}_{k, i, j}$$\end{document}</tex-math><mml:math id="M64"><mml:msub><mml:mtext>A</mml:mtext><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq23.gif"/></alternatives></inline-formula> represents the connection between the <inline-formula id="IEq24"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i^{th}$$\end{document}</tex-math><mml:math id="M66"><mml:msup><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="italic">th</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq24.gif"/></alternatives></inline-formula> EGFR atom and the <inline-formula id="IEq25"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j^{th}$$\end{document}</tex-math><mml:math id="M68"><mml:msup><mml:mi>j</mml:mi><mml:mrow><mml:mi mathvariant="italic">th</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq25.gif"/></alternatives></inline-formula> drug atom in the <inline-formula id="IEq26"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k^{th}$$\end{document}</tex-math><mml:math id="M70"><mml:msup><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">th</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq26.gif"/></alternatives></inline-formula> MD snapshot, and is 1 if there is a connection and zero otherwise. Let<disp-formula id="Equ9"><label>9</label><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} D_{k} = \sum _i C_{k, i} &gt; 0 \end{aligned}$$\end{document}</tex-math><mml:math id="M72" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ9.gif" position="anchor"/></alternatives></disp-formula>which represents number of connected atoms in the MD snapshot. The number of connected atoms over the entire trajectory was used as a feature.<disp-formula id="Equ10"><label>10</label><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} E_k = \frac{\sum {_{i = 1}^{N}} (D_{k, i})}{N} \end{aligned}$$\end{document}</tex-math><mml:math id="M74" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>∑</mml:mo><mml:msubsup><mml:mrow/><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ10.gif" position="anchor"/></alternatives></disp-formula></p>
      </sec>
      <sec id="Sec21">
        <title>Binding site positioning</title>
        <p id="Par38">The positioning is evaluated using the Euclidean distance between the EGFR binding site atoms and the center of the drug-molecule.<disp-formula id="Equ11"><label>11</label><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} D(a,b) = \sqrt{(x_a - x_b)^2 + (y_a - y_b)^2 +(z_a - z_b)^2} \end{aligned}$$\end{document}</tex-math><mml:math id="M76" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ11.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par39">The binding site residues are represented by their alpha-carbon (CA) atoms. For example, if there are 14 CA atoms at the binding site, and two atoms at the drug molecule center, then a 14 <inline-formula id="IEq27"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M78"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq27.gif"/></alternatives></inline-formula> 2 or 28<inline-formula id="IEq28"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$~\times$$\end{document}</tex-math><mml:math id="M80"><mml:mrow><mml:mspace width="3.33333pt"/><mml:mo>×</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq28.gif"/></alternatives></inline-formula> 1 vector will represent this. The distance over the entire MD simulation of 200 frames can be represented as a 200<inline-formula id="IEq29"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$~\times ~$$\end{document}</tex-math><mml:math id="M82"><mml:mrow><mml:mspace width="3.33333pt"/><mml:mo>×</mml:mo><mml:mspace width="3.33333pt"/></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq29.gif"/></alternatives></inline-formula>28 matrix. The binding site position is represented as the average distance between the drug and the target:<disp-formula id="Equ12"><label>12</label><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} D_{avg} = \frac{\sum _{i = 1}^N (D_i)}{N} \end{aligned}$$\end{document}</tex-math><mml:math id="M84" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi mathvariant="italic">avg</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ12.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq30"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {D}_{{avg}}$$\end{document}</tex-math><mml:math id="M86"><mml:msub><mml:mtext>D</mml:mtext><mml:mrow><mml:mi mathvariant="italic">avg</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq30.gif"/></alternatives></inline-formula> shows the binding site position, <inline-formula id="IEq31"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {D}_i$$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mtext>D</mml:mtext><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq31.gif"/></alternatives></inline-formula> shows the ith MD snapshot distance, and <italic>N</italic> is the number of MD snapshots. All the feature values were normalized to [0,1]. Generally, drug sensitive mutants have less distance between the drug and the target.<fig id="Fig12"><label>Figure 12</label><caption><p>Geometric, energy and personal features and their distributions.</p></caption><graphic xlink:href="41598_2022_23649_Fig12_HTML" id="MO25"/></fig></p>
      </sec>
      <sec id="Sec22">
        <title>Hydrogen bonds</title>
        <p id="Par40">Hydrogen bonds contribute to the stability of a structure and can provide insights about interactions within the structure. Stable systems tend to have more hydrogen bonds. The number of hydrogen bonds in the EGFR-drug complex were calculated using the hbond command in Amber.</p>
      </sec>
      <sec id="Sec23">
        <title>Composite geometric features</title>
        <p id="Par41">The geometric features were combined to make two composite features, with the matching rate, number of connected atoms, and number of hydrogen bonds as one feature, <inline-formula id="IEq32"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g1}$$\end{document}</tex-math><mml:math id="M90"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq32.gif"/></alternatives></inline-formula> and the number of convex atoms and Euclidean distance, <inline-formula id="IEq33"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{g2}$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq33.gif"/></alternatives></inline-formula>, as the other. Similarly, the personal features and energy features were combined as <inline-formula id="IEq34"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_p$$\end{document}</tex-math><mml:math id="M94"><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq34.gif"/></alternatives></inline-formula> and <inline-formula id="IEq35"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$x_{e1}$$\end{document}</tex-math><mml:math id="M96"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq35.gif"/></alternatives></inline-formula>, respectively.</p>
      </sec>
    </sec>
    <sec id="Sec24">
      <title>Feature normalization</title>
      <p id="Par42">Each feature was normalized to the range [− 1, 1] using z-score normalization<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>.<disp-formula id="Equ13"><label>13</label><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} z_i = \frac{x_i - \mu }{\sigma } \end{aligned}$$\end{document}</tex-math><mml:math id="M98" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mi>σ</mml:mi></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ13.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq36"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$z_i$$\end{document}</tex-math><mml:math id="M100"><mml:msub><mml:mi>z</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq36.gif"/></alternatives></inline-formula> represents the normalized value, <inline-formula id="IEq37"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mu$$\end{document}</tex-math><mml:math id="M102"><mml:mi>μ</mml:mi></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq37.gif"/></alternatives></inline-formula> represents the mean value, and <inline-formula id="IEq38"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sigma$$\end{document}</tex-math><mml:math id="M104"><mml:mi>σ</mml:mi></mml:math><inline-graphic xlink:href="41598_2022_23649_Article_IEq38.gif"/></alternatives></inline-formula> represents the standard deviation value for each feature. Composite geometric features, energy features, clinical features and their density distributions are presented in Fig. <xref rid="Fig12" ref-type="fig">12</xref>.</p>
    </sec>
    <sec id="Sec25">
      <title>Development of the classification model</title>
      <p id="Par43">For patients with clinical information, geometrical and energy features were obtained from their EGFR mutant drug complex, and classifiers were trained to predict one of the four-classes of drug response level. Five popular classifiers i.e., KNN, SVM, Artificial Neural Network, Random Forest, and XGboost were tested using Python Scikit-learn<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and Tensorflow library<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. We also used CARET package<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> of RStudio for feature visualization plots. We used 141 samples for training the model. The parameters were optimized using a GridSearch approach. To ensure that the predictions made by the model are not by chance, we also performed y-scrambling and randomly shuffled the labels for 50 iterations. The mean accuracy drops down to 0.48587 from 0.975. To further avoid over-fitting and careful selection of hyper-parameters and model, we used a nested cross-validation function<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>, with an outer loop of 10 and inner loop of 3. The parameters are selected with a grid search of (10, 100, 500) estimators, (2, 4, 6, 10, 12) features and maximum depth of 3 for XGboost and Random Forest. The final proposed XGboost has a mean accuracy of 0.971 with a standard deviation of 0.035. The results vary between 0.8571 and 1 during cross validation. We also trained a neural network with four layers, with sigmoid activation for hidden layers and softmax for the output layer, for 8000 epochs. We used different activation functions, including Relu and dropout with different thresholds during the model selection. The categorical cross-entropy as the loss function, and RMSProp as an optimizer. We also implemented early stopping to monitor the validation loss with a patience value of 100. The source code is available on GitHub <ext-link ext-link-type="uri" xlink:href="https://github.com/rizwanqureshi123/PDRP">https://github.com/rizwanqureshi123/PDRP</ext-link>.</p>
    </sec>
    <sec id="Sec26">
      <title>Performance evaluation metrics</title>
      <p id="Par44">Classification model evaluation performance metrics used were precision, recall, F1-measure, and balanced accuracy defined as follows:<disp-formula id="Equ14"><label>14</label><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} Precision= &amp; {} \frac{TP}{TP + FP} \end{aligned}$$\end{document}</tex-math><mml:math id="M106" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">TP</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ14.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ15"><label>15</label><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} Recall= &amp; {} \frac{TP}{TP + FN} \end{aligned}$$\end{document}</tex-math><mml:math id="M108" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">TP</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ15.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ16"><label>16</label><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} F1-measure= &amp; {} \frac{2 \times Precision \times Recall}{Precision + Recall} \end{aligned}$$\end{document}</tex-math><mml:math id="M110" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>F</mml:mi><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ16.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ17"><label>17</label><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} Acc= &amp; {} \frac{TP + TN}{TP + TN + FP + FN} \end{aligned}$$\end{document}</tex-math><mml:math id="M112" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>c</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="41598_2022_23649_Article_Equ17.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par45">The terms TP, FP, FN, and TN denote true positive, false positive, false negative, and true negative, respectively.</p>
    </sec>
  </sec>
  <sec id="Sec27">
    <title>Conclusion</title>
    <p id="Par46">Computational methods, especially machine learning<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup> based techniques are widely used to predict responses to lung cancer drugs. In this work, we developed a machine learning based model (PDRP), that uses clinical and demographic information (DCI), energy, and geometrical features in machine learning classifiers to predict the four levels of drug response. PDRP achieved state-of-the-art performance at 97.5% accuracy with an XGBoost classifier, even though only a small number of patients’ had information available. Our model provides a personalized drug response level prediction with a highly accurate prediction rate that could be tested on other types of cancer or other diseases. PDRP shows that modeling geometry, even in silico, can provide a powerful biomarker to predict the drug response of lung cancer patients. In future, we will further explore the dynamics and geometry of the binding-sites of protein-drug complexes. More clinical data will be collected to further refine the prediction model, and test it on other diseases.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec28">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41598_2022_23649_MOESM1_ESM.xlsx">
            <caption>
              <p>Supplementary Information.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary Information</title>
    <p>The online version contains supplementary material available at 10.1038/s41598-022-23649-0.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>This work is supported by the Hong Kong Innovation and Technology Commission (InnoHK Project CIMDA), the Hong Kong Research Grants Council (Project 11204821) and City University of Hong Kong (Project 9610034). The open access publication of this article was funded by College of Science and Engineering, Hamad Bin Khalifa University (HBKU), Qatar.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>R.Q. contributed in conceptualization, experiments, writing, and modeling; S.A.B. contributed to developing the classification model and drawing illustrations; X.F. and M.N. assisted in modeling, conceptualization, and writing; H.Y. provided the dataset and assisted in revision of the manuscript; J.A.S. helped with writing the manuscript; T.A. contributed to conceiving, designing experiments, designing machine learning models, analysing results, writing manuscript.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>The datasets generated and/or analysed during the current study are not publicly available due non-disclosure agreement but are available from the corresponding author on reasonable request.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <mixed-citation publication-type="other">Siegel, R. L., Miller, K. D., Fuchs, H. E. &amp; Jemal, A. Cancer statistics, 2022. <italic>CA Cancer J. Clin.</italic> (2022).</mixed-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gupta</surname>
            <given-names>GP</given-names>
          </name>
          <name>
            <surname>Massagué</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Cancer metastasis: Building a framework</article-title>
        <source>Cell</source>
        <year>2006</year>
        <volume>127</volume>
        <fpage>679</fpage>
        <lpage>695</lpage>
        <?supplied-pmid 17110329?>
        <pub-id pub-id-type="pmid">17110329</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <mixed-citation publication-type="other">Qureshi, R. <italic>et al.</italic> Computational methods for the analysis and prediction of egfr-mutated lung cancer drug resistance: Recent advances in drug design, challenges and future prospects. <italic>IEEE/ACM Trans. Comput. Biol. Bioinform.</italic> (2022).</mixed-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kawaguchi</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Randomized phase iii trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (delta)</article-title>
        <source>J. Clin. Oncol.</source>
        <year>2014</year>
        <volume>32</volume>
        <fpage>1902</fpage>
        <lpage>1908</lpage>
        <?supplied-pmid 24841974?>
        <pub-id pub-id-type="pmid">24841974</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pao</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Egf receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</article-title>
        <source>Proc. Natl. Acad. Sci.</source>
        <year>2004</year>
        <volume>101</volume>
        <fpage>13306</fpage>
        <lpage>13311</lpage>
        <?supplied-pmid 15329413?>
        <pub-id pub-id-type="pmid">15329413</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer</article-title>
        <source>Drug Des. Dev. Ther.</source>
        <year>2016</year>
        <volume>10</volume>
        <fpage>3867</fpage>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Attri</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Bariwal</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Review on egfr inhibitors: Critical updates</article-title>
        <source>Mini Rev. Med. Chem.</source>
        <year>2016</year>
        <volume>16</volume>
        <fpage>1134</fpage>
        <lpage>1166</lpage>
        <?supplied-pmid 26996617?>
        <pub-id pub-id-type="pmid">26996617</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tetsu</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Hangauer</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Phuchareon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Eisele</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>McCormick</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Drug resistance to egfr inhibitors in lung cancer</article-title>
        <source>Chemotherapy</source>
        <year>2016</year>
        <volume>61</volume>
        <fpage>223</fpage>
        <lpage>235</lpage>
        <?supplied-pmid 26910730?>
        <pub-id pub-id-type="pmid">26910730</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rho</surname>
            <given-names>JK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by t790m mutation</article-title>
        <source>Mol. Cancer Ther.</source>
        <year>2010</year>
        <volume>9</volume>
        <fpage>3233</fpage>
        <lpage>3243</lpage>
        <?supplied-pmid 21159609?>
        <pub-id pub-id-type="pmid">21159609</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Balius</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Rizzo</surname>
            <given-names>RC</given-names>
          </name>
        </person-group>
        <article-title>Quantitative prediction of fold resistance for inhibitors of egfr</article-title>
        <source>Biochemistry</source>
        <year>2009</year>
        <volume>48</volume>
        <fpage>8435</fpage>
        <lpage>8448</lpage>
        <?supplied-pmid 19627157?>
        <pub-id pub-id-type="pmid">19627157</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tetsu</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Phuchareon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Eisele</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Hangauer</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>McCormick</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Akt inactivation causes persistent drug tolerance to egfr inhibitors</article-title>
        <source>Pharmacol. Res.</source>
        <year>2015</year>
        <volume>102</volume>
        <fpage>132</fpage>
        <lpage>137</lpage>
        <?supplied-pmid 26453958?>
        <pub-id pub-id-type="pmid">26453958</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guardiola</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Varese</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sánchez-Navarro</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Giralt</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>A third shot at egfr: New opportunities in cancer therapy</article-title>
        <source>Trends Pharmacol. Sci.</source>
        <year>2019</year>
        <volume>40</volume>
        <fpage>941</fpage>
        <lpage>955</lpage>
        <?supplied-pmid 31706618?>
        <pub-id pub-id-type="pmid">31706618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>Personalized prediction of egfr mutation-induced drug resistance in lung cancer</article-title>
        <source>Sci. Rep.</source>
        <year>2013</year>
        <volume>3</volume>
        <fpage>1</fpage>
        <lpage>8</lpage>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karplus</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>McCammon</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>Molecular dynamics simulations of biomolecules</article-title>
        <source>Nat. Struct. Biol.</source>
        <year>2002</year>
        <volume>9</volume>
        <fpage>646</fpage>
        <lpage>652</lpage>
        <?supplied-pmid 12198485?>
        <pub-id pub-id-type="pmid">12198485</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <mixed-citation publication-type="other">Qureshi, R., Ghosh, A. &amp; Yan, H. Correlated motions and dynamics in different domains of egfr with l858r and t790m mutations. <italic>IEEE/ACM Trans. Comput. Biol. Bioinform.</italic> (2020).</mixed-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Coveney</surname>
            <given-names>PV</given-names>
          </name>
        </person-group>
        <article-title>Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor</article-title>
        <source>J. Comput. Chem.</source>
        <year>2011</year>
        <volume>32</volume>
        <fpage>2843</fpage>
        <lpage>2852</lpage>
        <?supplied-pmid 21717480?>
        <pub-id pub-id-type="pmid">21717480</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <mixed-citation publication-type="other">Qureshi, R., Zhu, M., Ghosh, A. &amp; Yan, H. Computational analysis of structural dynamics of egfr and its mutants. in <italic>2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</italic>, 2784–2791 (IEEE, 2019).</mixed-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <mixed-citation publication-type="other">Rizwan, Q., Zhu, M. &amp; Yan, H. Visualization of protein-drug interactions for the analysis of drug resistance in lung cancer. <italic>IEEE J. Biomed. Health Inform.</italic>(2020).</mixed-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Apatinib to combat egfr-tki resistance in an advanced non-small cell lung cancer patient with unknown egfr status: A case report</article-title>
        <source>Onco Targets Ther.</source>
        <year>2017</year>
        <volume>10</volume>
        <fpage>2289</fpage>
        <?supplied-pmid 28490886?>
        <pub-id pub-id-type="pmid">28490886</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mehner</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Egfr as a prognostic biomarker and therapeutic target in ovarian cancer: Evaluation of patient cohort and literature review</article-title>
        <source>Genes Cancer</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>589</fpage>
        <?supplied-pmid 28740577?>
        <pub-id pub-id-type="pmid">28740577</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Collins</surname>
            <given-names>FS</given-names>
          </name>
          <name>
            <surname>Morgan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Patrinos</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The human genome project: Lessons from large-scale biology</article-title>
        <source>Science</source>
        <year>2003</year>
        <volume>300</volume>
        <fpage>286</fpage>
        <lpage>290</lpage>
        <?supplied-pmid 12690187?>
        <pub-id pub-id-type="pmid">12690187</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashley</surname>
            <given-names>EA</given-names>
          </name>
        </person-group>
        <article-title>Towards precision medicine</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>507</fpage>
        <lpage>522</lpage>
        <?supplied-pmid 27528417?>
        <pub-id pub-id-type="pmid">27528417</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hoerbst</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ammenwerth</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Electronic health records</article-title>
        <source>Methods Inf. Med.</source>
        <year>2010</year>
        <volume>49</volume>
        <fpage>320</fpage>
        <lpage>336</lpage>
        <?supplied-pmid 20603687?>
        <pub-id pub-id-type="pmid">20603687</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mok</surname>
            <given-names>TS</given-names>
          </name>
        </person-group>
        <article-title>Personalized medicine in lung cancer: What we need to know</article-title>
        <source>Nat. Rev. Clin. Oncol.</source>
        <year>2011</year>
        <volume>8</volume>
        <fpage>661</fpage>
        <lpage>668</lpage>
        <?supplied-pmid 21862980?>
        <pub-id pub-id-type="pmid">21862980</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>French</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Statistical design of personalized medicine interventions: The clarification of optimal anticoagulation through genetics (coag) trial</article-title>
        <source>Trials</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>1</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="pmid">20059766</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>An eigen-binding site based method for the analysis of anti-egfr drug resistance in lung cancer treatment</article-title>
        <source>IEEE/ACM Trans. Comput. Biol. Bioinform.</source>
        <year>2016</year>
        <volume>14</volume>
        <fpage>1187</fpage>
        <lpage>1194</lpage>
        <?supplied-pmid 27187970?>
        <pub-id pub-id-type="pmid">27187970</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <mixed-citation publication-type="other">Basit, S. A., Qureshi, R., Shahid, A. R. &amp; Khan, S. Survival prediction of lung cancer patients by integration of clinical and molecular features using machine learning. in <italic>2021 15th International Conference on Open Source Systems and Technologies (ICOSST)</italic>, 1–6 (IEEE, 2021).</mixed-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berman</surname>
            <given-names>HM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The protein data bank</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2000</year>
        <volume>28</volume>
        <fpage>235</fpage>
        <lpage>242</lpage>
        <?supplied-pmid 10592235?>
        <pub-id pub-id-type="pmid">10592235</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Taxirec: Recommending road clusters to taxi drivers using ranking-based extreme learning machines</article-title>
        <source>IEEE Trans. Knowl. Data Eng.</source>
        <year>2018</year>
        <volume>30</volume>
        <fpage>585</fpage>
        <lpage>598</lpage>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <mixed-citation publication-type="other">Duan, B., Zou, B., Wang, D. D., Yan, H. &amp; Han, L. Computational evaluation of egfr dynamic characteristics in mutation-induced drug resistance prediction. in <italic>2015 IEEE International Conference on Systems, Man, and Cybernetics</italic>, 2299–2304 (IEEE, 2015).</mixed-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zou</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>VH</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Prediction of sensitivity to gefitinib/erlotinib for egfr mutations in nsclc based on structural interaction fingerprints and multilinear principal component analysis</article-title>
        <source>BMC Bioinform.</source>
        <year>2018</year>
        <volume>19</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>VH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Association of exon 19 and 21 egfr mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer</article-title>
        <source>J. Thoracic Oncol.</source>
        <year>2013</year>
        <volume>8</volume>
        <fpage>1148</fpage>
        <lpage>1155</lpage>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Egfr mutant structural database: Computationally predicted 3d structures and the corresponding binding free energies with gefitinib and erlotinib</article-title>
        <source>BMC Bioinform.</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>1</fpage>
        <lpage>10</lpage>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zou</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Deciphering mechanisms of acquired t790m mutation after egfr inhibitors for nsclc by computational simulations</article-title>
        <source>Sci. Rep.</source>
        <year>2017</year>
        <volume>7</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="pmid">28127051</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Salomon-Ferrer</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Case</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>RC</given-names>
          </name>
        </person-group>
        <article-title>An overview of the amber biomolecular simulation package</article-title>
        <source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source>
        <year>2013</year>
        <volume>3</volume>
        <fpage>198</fpage>
        <lpage>210</lpage>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <mixed-citation publication-type="other">Rohl, C. A., Strauss, C. E., Misura, K. M. &amp; Baker, D. Protein structure prediction using rosetta. in <italic>Methods in Enzymology</italic>, vol. 383, 66–93 (Elsevier, 2004).</mixed-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <mixed-citation publication-type="other">Lencioni, R. &amp; Llovet, J. M. Modified recist (mrecist) assessment for hepatocellular carcinoma. in <italic>Seminars in Liver Disease</italic>, vol. 30, 052–060 (Thieme Medical Publishers, 2010).</mixed-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cova</surname>
            <given-names>TF</given-names>
          </name>
          <name>
            <surname>Pais</surname>
            <given-names>AA</given-names>
          </name>
        </person-group>
        <article-title>Deep learning for deep chemistry: Optimizing the prediction of chemical patterns</article-title>
        <source>Front. Chem.</source>
        <year>2019</year>
        <volume>7</volume>
        <fpage>809</fpage>
        <?supplied-pmid 32039134?>
        <pub-id pub-id-type="pmid">32039134</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kureshi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Abidi</surname>
            <given-names>SSR</given-names>
          </name>
          <name>
            <surname>Blouin</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>A predictive model for personalized therapeutic interventions in non-small cell lung cancer</article-title>
        <source>IEEE J. Biomed. Health Inform.</source>
        <year>2014</year>
        <volume>20</volume>
        <fpage>424</fpage>
        <lpage>431</lpage>
        <?supplied-pmid 25494516?>
        <pub-id pub-id-type="pmid">25494516</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bamford</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The cosmic (catalogue of somatic mutations in cancer) database and website</article-title>
        <source>Br. J. Cancer</source>
        <year>2004</year>
        <volume>91</volume>
        <fpage>355</fpage>
        <lpage>358</lpage>
        <?supplied-pmid 15188009?>
        <pub-id pub-id-type="pmid">15188009</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Molecular dynamics simulations with quantum mechanics/molecular mechanics and adaptive neural networks</article-title>
        <source>J. Chem. Theory Comput.</source>
        <year>2018</year>
        <volume>14</volume>
        <fpage>1442</fpage>
        <lpage>1455</lpage>
        <?supplied-pmid 29438614?>
        <pub-id pub-id-type="pmid">29438614</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kobayashi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mitsudomi</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy</article-title>
        <source>Cancer Sci.</source>
        <year>2016</year>
        <volume>107</volume>
        <fpage>1179</fpage>
        <lpage>1186</lpage>
        <?supplied-pmid 27323238?>
        <pub-id pub-id-type="pmid">27323238</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kellogg</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Leaver-Fay</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Role of conformational sampling in computing mutation-induced changes in protein structure and stability</article-title>
        <source>Proteins Struct. Funct. Bioinform.</source>
        <year>2011</year>
        <volume>79</volume>
        <fpage>830</fpage>
        <lpage>838</lpage>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martí-Renom</surname>
            <given-names>MA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comparative protein structure modeling of genes and genomes</article-title>
        <source>Annu. Rev. Biophys. Biomol. Struct.</source>
        <year>2000</year>
        <volume>29</volume>
        <fpage>291</fpage>
        <lpage>325</lpage>
        <?supplied-pmid 10940251?>
        <pub-id pub-id-type="pmid">10940251</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <mixed-citation publication-type="other">Eisenberg, D., Lüthy, R. &amp; Bowie, J. U. verify3d: Assessment of protein models with three-dimensional profiles. in <italic>Methods in enzymology,</italic> vol. 277, 396–404 (Elsevier, 1997).</mixed-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thakur</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Dharra</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Saini</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>PK</given-names>
          </name>
        </person-group>
        <article-title>Insights from the protein-protein interaction network analysis of mycobacterium tuberculosis toxin-antitoxin systems</article-title>
        <source>Bioinformation</source>
        <year>2017</year>
        <volume>13</volume>
        <fpage>380</fpage>
        <?supplied-pmid 29225431?>
        <pub-id pub-id-type="pmid">29225431</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Case</surname>
            <given-names>DA</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Amber 10</source>
        <year>2008</year>
        <publisher-name>University of California</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>C-Y</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y-D</given-names>
          </name>
        </person-group>
        <article-title>Residue-specific force field based on protein coil library rsff2: Modification of amber ff99sb</article-title>
        <source>J. Phys. Chem. B</source>
        <year>2015</year>
        <volume>119</volume>
        <fpage>1035</fpage>
        <lpage>1047</lpage>
        <?supplied-pmid 25358113?>
        <pub-id pub-id-type="pmid">25358113</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kräutler</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Van Gunsteren</surname>
            <given-names>WF</given-names>
          </name>
          <name>
            <surname>Hünenberger</surname>
            <given-names>PH</given-names>
          </name>
        </person-group>
        <article-title>A fast shake algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations</article-title>
        <source>J. Comput. Chem.</source>
        <year>2001</year>
        <volume>22</volume>
        <fpage>501</fpage>
        <lpage>508</lpage>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aktulga</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Fogarty</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Pandit</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Grama</surname>
            <given-names>AY</given-names>
          </name>
        </person-group>
        <article-title>Parallel reactive molecular dynamics: Numerical methods and algorithmic techniques</article-title>
        <source>Parallel Comput.</source>
        <year>2012</year>
        <volume>38</volume>
        <fpage>245</fpage>
        <lpage>259</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gotz</surname>
            <given-names>AW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Routine microsecond molecular dynamics simulations with amber on gpus. 1. generalized born</article-title>
        <source>J. Chem. Theor. Comput.</source>
        <year>2012</year>
        <volume>8</volume>
        <fpage>1542</fpage>
        <lpage>1555</lpage>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roe</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Cheatham</surname>
            <given-names>TE</given-names>
            <suffix>III</suffix>
          </name>
        </person-group>
        <article-title>Ptraj and cpptraj: Software for processing and analysis of molecular dynamics trajectory data</article-title>
        <source>J. Chem. Theor. Comput.</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>3084</fpage>
        <lpage>3095</lpage>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gohlke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kiel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Case</surname>
            <given-names>DA</given-names>
          </name>
        </person-group>
        <article-title>Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the ras-raf and ras-ralgds complexes</article-title>
        <source>J. Mol. Biol.</source>
        <year>2003</year>
        <volume>330</volume>
        <fpage>891</fpage>
        <lpage>913</lpage>
        <?supplied-pmid 12850155?>
        <pub-id pub-id-type="pmid">12850155</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Öztürk</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Özgür</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ozkirimli</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Deepdta: Deep drug-target binding affinity prediction</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>i821</fpage>
        <lpage>i829</lpage>
        <?supplied-pmid 30423097?>
        <pub-id pub-id-type="pmid">30423097</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Genheden</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ryde</surname>
            <given-names>U</given-names>
          </name>
        </person-group>
        <article-title>The mm/pbsa and mm/gbsa methods to estimate ligand-binding affinities</article-title>
        <source>Expert Opin. Drug Discov.</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>449</fpage>
        <lpage>461</lpage>
        <?supplied-pmid 25835573?>
        <pub-id pub-id-type="pmid">25835573</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reddy</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Erion</surname>
            <given-names>MD</given-names>
          </name>
        </person-group>
        <article-title>Calculation of relative binding free energy differences for fructose 1, 6-bisphosphatase inhibitors using the thermodynamic cycle perturbation approach</article-title>
        <source>J. Am. Chem. Soc.</source>
        <year>2001</year>
        <volume>123</volume>
        <fpage>6246</fpage>
        <lpage>6252</lpage>
        <?supplied-pmid 11427047?>
        <pub-id pub-id-type="pmid">11427047</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Naderi</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Binding site matching in rational drug design: Algorithms and applications</article-title>
        <source>Brief. Bioinform.</source>
        <year>2019</year>
        <volume>20</volume>
        <fpage>2167</fpage>
        <lpage>2184</lpage>
        <?supplied-pmid 30169563?>
        <pub-id pub-id-type="pmid">30169563</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wilson</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Bender</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kaya</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Clemons</surname>
            <given-names>PA</given-names>
          </name>
        </person-group>
        <article-title>Alpha shapes applied to molecular shape characterization exhibit novel properties compared to established shape descriptors</article-title>
        <source>J. Chem. Inf. Model.</source>
        <year>2009</year>
        <volume>49</volume>
        <fpage>2231</fpage>
        <lpage>2241</lpage>
        <?supplied-pmid 19775113?>
        <pub-id pub-id-type="pmid">19775113</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fabri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Giezeman</surname>
            <given-names>G-J</given-names>
          </name>
          <name>
            <surname>Kettner</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Schirra</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schönherr</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>On the design of cgal a computational geometry algorithms library</article-title>
        <source>Softw. Pract. Exp.</source>
        <year>2000</year>
        <volume>30</volume>
        <fpage>1167</fpage>
        <lpage>1202</lpage>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Identifying egfr mutation-induced drug resistance based on alpha shape model analysis of the dynamics</article-title>
        <source>Proteome Sci.</source>
        <year>2016</year>
        <volume>14</volume>
        <fpage>12</fpage>
        <?supplied-pmid 27610045?>
        <pub-id pub-id-type="pmid">27610045</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Saranya</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Manikandan</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>A study on normalization techniques for privacy preserving data mining</article-title>
        <source>Int. J. Eng. Technol. (IJET)</source>
        <year>2013</year>
        <volume>5</volume>
        <fpage>2701</fpage>
        <lpage>2704</lpage>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pedregosa</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Scikit-learn: Machine learning in python</article-title>
        <source>J. Mach. Learn. Res.</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>2825</fpage>
        <lpage>2830</lpage>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Géron</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <source>Hands-on Machine Learning with Scikit-Learn, Keras, and TensorFlow: Concepts, Tools, and Techniques to Build Intelligent Systems</source>
        <year>2019</year>
        <publisher-name>O’Reilly Media Inc</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kuhn</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Building predictive models in r using the caret package</article-title>
        <source>J. Stat. Softw.</source>
        <year>2008</year>
        <volume>28</volume>
        <fpage>1</fpage>
        <lpage>26</lpage>
        <pub-id pub-id-type="pmid">27774042</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Parvandeh</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yeh</surname>
            <given-names>H-W</given-names>
          </name>
          <name>
            <surname>Paulus</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>McKinney</surname>
            <given-names>BA</given-names>
          </name>
        </person-group>
        <article-title>Consensus features nested cross-validation</article-title>
        <source>Bioinformatics</source>
        <year>2020</year>
        <volume>36</volume>
        <fpage>3093</fpage>
        <lpage>3098</lpage>
        <?supplied-pmid 31985777?>
        <pub-id pub-id-type="pmid">31985777</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Frunza</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Inkpen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>A machine learning approach for identifying disease-treatment relations in short texts</article-title>
        <source>IEEE Trans. Knowl. Data Eng.</source>
        <year>2010</year>
        <volume>23</volume>
        <fpage>801</fpage>
        <lpage>814</lpage>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hao</surname>
            <given-names>G-F</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>G-F</given-names>
          </name>
          <name>
            <surname>Zhan</surname>
            <given-names>C-G</given-names>
          </name>
        </person-group>
        <article-title>Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem</article-title>
        <source>Drug Discov. Today</source>
        <year>2012</year>
        <volume>17</volume>
        <fpage>1121</fpage>
        <lpage>1126</lpage>
        <?supplied-pmid 22789991?>
        <pub-id pub-id-type="pmid">22789991</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
